Compare AIP & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIP | IMTX |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2021 | N/A |
| Metric | AIP | IMTX |
|---|---|---|
| Price | $36.40 | $11.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $16.83 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.1M | 454.9K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,579,000.00 | N/A |
| Revenue This Year | $30.24 | N/A |
| Revenue Next Year | $19.50 | $25.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.27 | N/A |
| 52 Week Low | $7.15 | $4.93 |
| 52 Week High | $38.47 | $12.41 |
| Indicator | AIP | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.15 | 59.70 |
| Support Level | $13.77 | $9.24 |
| Resistance Level | $38.47 | $12.00 |
| Average True Range (ATR) | 2.49 | 0.61 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 77.38 | 89.20 |
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum its revenue from Asia Pacific.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.